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Abstract
Background:  Although  a  number  of  studies  in  patients  with  a  variety  of  malignant  tumors  have
shown that  metabolic  activity  on  ﬂuorine-18  deoxyglucose  positron  emission  tomography  com-
puted tomography  (18F-FDG-PET/CT)  is  correlated  with  survival,  there  are  few  studies  about
the impact  of 18F-FDG-PET/CT  for  survival  in  small  cell  lung  cancer  (SCLC)  patients.  There  is  still
some ambiguity  as  to  whether  FDG  PET  in  patients  with  SCLC  will  ensure  prognostic  knowledge
for survival.  We  performed  a  retrospective  analysis  of  prognostic  implication  of 18F-FDG-PET/CT
in patients  with  SCLC.
Methods:  We  retrospectively  reviewed  54  patients  with  histologically  or  cytologically  proven
SCLC who  had  undergone  pre-treatment 18F-FDG-PET/CT  scanning  between  September  2007
and November  2011  in  the  Dicle  University,  School  of  Medicine,  Department  of  Medical  Oncol-
ogy. SUVmax  and  other  potential  prognostic  variables  were  chosen  for  analysis  in  this  study.
Univariate  and  multivariate  analyses  were  conducted  to  identify  prognostic  factors  associated
with survival.
Result:  Among  the  eleven  variables  of  univariate  analysis,  three  variables  were  identiﬁed  as
having prognostic  signiﬁcance:  Performance  status  (p  <  0.001),  stage  (p  =  0.02)  and  diabetes
mellitus (p  =  0.05).
Multivariate  analysis  showed  that  performance  status  and  stage  were  considered  independent
prognostic  factors  for  survival  (p  <  0.001  and  p  =  0.002  respectively).
Conclusion:  In  conclusion,  performance  status  and  stage  were  identiﬁed  as  important  prognostic
18 CT  uptake  of  the  primary  lesions  was  not  associated  with  prognosticfactors, while F-FDG-PET/
importance  for  survival  in  patients  with  SCLC.
© 2012  Sociedade  Portuguesa  de  Pneumologia.  Published  by  Elsevier  España,  S.L.  All  rights
reserved.
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PALAVRAS-CHAVE
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É  o 18F  -FDG-PET/CT  um  fator  de  prognóstico  para  a  sobrevivência  em  pacientes
com  cancro  pulmonar  de  pequenas  células?  Experiência  num  único  centro
Resumo
Antecedentes:  Embora  uma  série  de  estudos  em  pacientes  com  uma  diversidade  de  tumores
malignos tenham  demonstrado  que  a  atividade  metabólica  na  tomograﬁa  computorizada  por
emissão de  positrões  de  deoxiglucose  marcada  com  ﬂúor-18  (18F-FDG-PET/CT)  está  correla-
cionada  com  a  sobrevivência,  existem  poucos  estudos  sobre  o  impacto  do 18F-FDG-PET/CT  para
a sobrevivência  em  pacientes  com  cancro  pulmonar  de  células  pequenas  (SCLC).  Ainda  existe
alguma ambiguidade  de  que,  em  pacientes  com  SCLC,  o  FDG  PET  fornec¸a  informac¸ões  impor-
tantes relativamente  de  prognóstico  para  a  sobrevivência.  Realizámos  uma  análise  retrospetiva
da implicac¸ão  no  prognóstico  de 18F-FDG-PET/CT  em  pacientes  com  SCLC.
Métodos:  Analisámos  retrospetivamente  54  pacientes  com  SCLC  comprovado  histologicamente
ou citologicamente,  que  tinham  realizado 18F-FDG-PET/CT  entre  setembro  de  2007  e  novembro
de 2011,  na  Universidade  de  Dicle,  Faculdade  de  Medicina,  Departamento  de  Oncologia  Médica.
Foram escolhidas  a  SUVmax  e  outras  potenciais  variáveis  de  prognóstico  para  a  análise  neste
estudo. Foram  realizadas  análises  univariadas  e  multivariadas  para  identiﬁcar  os  fatores  de
prognóstico  associados  à  sobrevivência.
Resultado:  Entre  as  11  variáveis  da  análise  univariada,  3  variáveis  foram  identiﬁcadas  como
tendo signiﬁcância  para  o  prognóstico.  Estado  Geral  (p  <  0,001),  estádio  (p  =  0,02)  e  diabetes
mellitus (p  =  0,05).
A  análise  multivariada  mostrou  que  o  Estado  Geral  e  o  estádio  foram  considerados  fatores  de
prognóstico  independentes  para  a  sobrevivência  (p  <  0,001,  p  =  0,002  respetivamente).
Conclusão:  Em  conclusão,  o  Estado  Geral  e  o  estádio  foram  identiﬁcados  como  importantes
fatores de  prognóstico,  enquanto  a  absorc¸ão  de 18F-FDG-PET/CT  das  lesões  primárias  não  se
associou ao  prognóstico  para  a  sobrevivência  em  pacientes  com  SCLC.
© 2012  Sociedade  Portuguesa  de  Pneumologia.  Publicado  por  Elsevier  España,  S.L.  Todos  os
direitos reservados.
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aIntroduction
Lung  cancer  is  the  most  common  among  cancer-related
deaths  in  both  men  and  women  in  worldwide.  Small  cell
lung  cancer  (SCLC)  represents  approximately  15%  of  all
diagnosed  lung  cancers  cases.1,2 SCLC  is  associated  with  a
more  rapid  tumor  doubling  time,  a  high  growth  fraction  and
early  widespread  dissemination.  As  a  result  of  this,  overall
survival  (OS)  rates  for  these  patients  are  disappointingly  low.
The  Veterans  Administration  Lung  Study  Group  two-
tiered  staging  system  was  used  to  classify  SCLC  as  either
limited  disease  (LD)  or  extended  disease  (ED)  which  was
primarily  based  on  compatibility  for  treatment  options.3
Despite  its  practical  usefulness  and  prognostic  advantage,
this  staging  system  is  not  accurate  enough  to  reﬂect  tumor
burden,  and  it  is  insufﬁcient  to  predict  survival  in  some
patients.
Very  different  prognostic  factors  in  several  trials  have
been  identiﬁed  for  survival  in  patients  with  SCLC4--7;
however,  none  of  these  prognostic  factors  are  sufﬁciently
reliable  to  base  treatment  decision  on.  Even  though
ﬂuorine-18  deoxyglucose  positron  emission  tomography
computed  tomography  (18F-FDG-PET/CT)  scan  is  widely
utilized  in  staging  SCLC,  it  is  not  standard  work-up  for
SCLC  with  respect  to  international  guidelines.  Owing  to  the
fact  that  a  number  of  studies  in  patients  with  a  variety  of
malignant  tumours8--13 have  shown  that  metabolic  activity
on 18F-FDG-PET/CT  is  correlated  with  survival,  there  are
few  studies  about  the  impact  of 18F-FDG-PET/CT  for  survival
c
i
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Cn  SCLC  patients.14--17 There  remains  an  ambiguity  as  to
hether 18F-FDG-PET/CT  in  patients  receiving  ﬁrst-line
toposide  plus  cisplatin  (EP)  chemotherapy  will  provide
eliable  prognostic  knowledge  about  survival.
We  performed  a  retrospective  analysis  of  the  progno-
tic  implication  of 18F-FDG-PET/CT  for  patients  with  SCLC.
he  aim  of  this  study  was  to  investigate  the  prognostic
igniﬁcance  of  the  characteristics  of  patients  in  SCLC.
peciﬁcally,  we  investigated  the  prognostic  implication  of
8F-FDG-PET/CT  for  OS  in  the  patients  receiving  ﬁrst-line  EP
hemotherapy.
ethods
atient  population
e  retrospectively  reviewed  54  patients  with  histologi-
ally  or  cytologically  proven  SCLC  who  had  undergone
re-treatment 18F-FDG-PET/CT  scanning  from  September
007  to  November  2011  in  the  Dicle  University,  School  of
edicine,  Department  of  Medical  Oncology.  They  met  the
ollowing  inclusion  criteria;  (1)  18  or  more  years  old;  (2)
 histologic  or  cytologic  diagnosis  of  SCLC;  (3)  no  previous
hemotherapy  or  radiotherapy;  (4)  there  was  sufﬁcient  clin-
cal  data  recorded  in  medical  records;  (5)  they  had  to  have
 measurable  disease,  as  deﬁned  by  Response  Evaluation
riteria  in  Solid  Tumours  (RECIST).
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Patients  were  identiﬁed  as  having  DM  on  the  basis  of  ele-
ated  fasting  glucose  level  (>126  mg/dL),  and  a  history  of
M  or  medication  use,  such  as  insulin  or  oral  hypoglycemic
gents.
Patients  with  LD  underwent  concurrent  chemoradio-
herapy,  which  consisted  of  chemotherapy  and  thoracic
adiotherapy.  Both  LD  and  ED  patients  were  receiving
rst-line  EP  chemotherapy.  The  EP  regimen  consisted  of
00  mg/m2 etoposide  on  days  1  and  30  mg/m2 cisplatin  on
ays  1--3,  every  3  weeks.
All  had  SCLC.  Patients  who  had  received  prior  treatment
ere  excluded.
DG-PET  imaging
DG-PET  was  carried  out  in  all  cases  within  6  weeks  before
RBT.  All  patients  fasted  for  at  least  4  h  before  the 18F-FDG-
ET/CT  examination  though  oral  hydration  with  glucose-free
ater  was  given.  When  peripheral  blood  glucose  level
efore  administration  of 18F-FDG  was  <150  mg/dL,  patients
eceived  an  intravenous  injection  of  3.70--4.44  MBq/kg  of
DG.  Whole-body  FDG-PET  was  scanned  using  the  same  scan-
er,  Biograph  6  PET/CT  scanner  (CTI/Siemens,  Knoxville,
N).  The  axes  of  both  systems  were  mechanically  aligned
o  that  the  patient  could  be  moved  from  the  CT  scan-
er  to  the  PET  scanner  gantry.  The  resulting  of  PET  and
T  scans  co-registered  on  the  same  hardware.  Then,  1
our  after  the  injection,  CT  and  PET  scans  were  per-
ormed.  Images  from  the  level  of  the  middle  skull  to  the
roximal  thigh  were  obtained.  CT  scan  was  implemented
ith  the  following  settings:  110  kV;  80  mA;  tube  rotation
ime,  0.8  s/rotation  per  pitch,  and  section  thickness,  3.0  mm
whole  body  CT  had  307  or  356  slices).  The  PET  and  CT
cans  were  obtained  during  normal  tidal  breathing.  The
ET  scans  were  done  immediately  after  the  CT  scans.  The
ET/CT  scans  were  obtained  in  3D  mode  at  3  min  per  bed
osition.
As  a  semi-quantitative  analysis,  the  maximum  standard-
zed  uptake  value  (SUVmax)  was  achieved  by  placing  region
f  interest  (ROIs)  over  the  lesions  that  had  been  determined
s  suspicious  on  visual  assessment.  SUVmax  of  the  pulmonary
umor  was  calculated  in  all  cases  using  a  3D  acquisition  and
he  following  formula:
UV = Mean ROI activity (MBq/ml)/Injected dose (MBq)
Body weight (g)
× 1
decay factor of F-18
The  maximum  standardized  uptake  value  (SUVmax)  was
epresented  by  the  counts  per  second  of  the  voxel  show-
ng  the  maximum  radioactivity  in  the  volume  of  interest
ncompassing  the  tumor  divided  by  the  volume  of  the  voxel
mL).
PET  data  were  iteratively  reconstructed  using  an  ordered
ubset  expectation  maximization  algorithm  and  segmented
ttenuation  correction  (2  iterations,  8  subsets)  and  the  CT
ata.  Co-registered  scans  were  displayed  using  dedicated
oftware  (e-soft-PET;  Siemens  Medical  Solutions).
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Two  experienced  nuclear  medicine  physicians,  who  were
naware  of  the  clinical  results,  viewed  and  quantitatively
nalyzed  the  PET  images.
actors  analyzed
leven  potential  prognostic  variables  were  chosen  on  the
asis  of  previously  published  clinical  trials.  The  variables
ere  divided  into  categories:  age  (<65  or  ≥65),  gender
male  or  female),  performance  status  (PS)  (0--1,  2--3),
tage  (LD  or  ED),  weight  loss  ≥5%  with  previous  3 months
present  or  absent),  diabetes  mellitus  (present  or  absent),
moking  history  (present  or  absent),  SUVmax  values  (<13.0
r  ≥13.0),  laboratory  parameters  [(albumin,  LDH,  blood
ugar)  (<median  or  ≥median)]  at  the  time  of  ﬁrst-line
hemotherapy  administration.
The  values  of  SUVmax  were  detected  between  5  and  20  in
rior  studies  with  log-rank  probability  values  to  determine  a
rognostic  cutoff  point  for  SUVmax.  Because  no  statistically
igniﬁcant  value  was  found,  SUVmax  was  dichotomized  at  its
edian  of  12.9  in  present  study.
tatistical  analysis
ll  of  the  analyses  were  performed  using  the  SPSS  statistical
oftware  program  package  (SPSS  version  11.5  for  windows).
he  differences  in  the  clinical  characteristics  between  the
wo  groups  were  analyzed  by  chi-square  test  and  student  t
est.  Overall  survival  (OS)  was  calculated  from  the  start  of
he  ﬁrst  cycle  of  chemotherapy  to  the  date  of  death  from
ny  cause  or  the  date  of  the  last  follow-up.  Overall  survival
as  estimated  using  the  Kaplan--Meier  method.  The  Cox  pro-
ortional  hazards  regression  model  was  used  to  determine
tatistical  signiﬁcant  variables  related  to  survival.  Differ-
nces  were  assumed  to  be  signiﬁcant  when  p  value  was  less
han  0.05.
esults
atient  characteristics
etween  September  2007  and  November  2011,  54  patients
ith  SCLC  were  enrolled  in  this  study.  The  median  age  of
atients  was  57  years  (range  28--80)  with  50  (92.6%)  males
nd  4  (7.4%)  females.  The  number  of  patients  with  a  PS
core  0--1  was  34  (63.0%).  Thirty  patients  (55.6%)  were  diag-
osed  as  having  extended  disease  and  24  patients  (44.4%)
ad  limited  disease.  The  estimated  median  OS  with  LD  was
7.3  months  (95%  CI,  8.9--25.7  months).  Median  OS  of
he  treated  ED  patients  was  8.4  months  (95%  CI,  7.1--9.8
onths).  The  patients’  baseline  characteristics  are  listed  in
able  1.
rognostic  factor  analysis
he  results  of  univariate  analysis  are  summarized  in
able  2.  Among  the  eleven  variables  of  univariate  analysis,
hree  variables  were  identiﬁed  as  having  prognostic
igniﬁcance:  Performance  status  (p  <  0.001),  stage
p  =  0.02)  and  diabetes  mellitus  (p  =  0.05).  Multivariate
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Table  1  The  general  characteristics  of  the  patients.
Characteristic  No.  of  patients  (%)
Sex
Male  50  (92.6)
Female  4  (7.4)
Age, median  (range)  57  (28--80)
Age
<65 47  (87.0)
≥65 7  (13.0)
Performance  status
0--1 34  (63.0)
2--3 18  (33.3)
Unknown  2  (3.7)
Smoking  history
Current  or  former  46  (85.2)
Never 4  (7.4)
Unknown  4  (7.4)
Weight  loss
Yes  34  (63.0)
No 11  (20.4)
Unknown  9  (16.6)
Diabetes  mellitus
Yes  40  (74.1)
No 4  (7.4)
Unknown  10  (18.5)
Stage
LD 24  (44.4)
ED 30  (55.6)
SUVmax,  median  13  (4.2--29.0)
Laboratory  parameters,  median
Albumin,  g/dl  3.4
Table  3  Multivariate  analysis  of  prognostic  factors.
Parameter  OR  %95  CI  p-Value
Performance  status  6.19  2.42--15.8  <0.001
Stage 6.46  1.93--21.5  0.002
1,0
0,8
0,6
0,4
0,2
Performance
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Figure  1  Survival  of  patients  according  to  performance  sta-
tus.
1,0 Stage
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lLDH, U/l 248
Blood  sugar,  mg/dl 103
analysis  included  the  three  prognostic  signiﬁcance  factors
in  univariate  analysis.  The  results  of  multivariate  anal-
ysis  are  shown  in  Table  3.  Multivariate  analysis  by
Cox  proportional  hazard  model  showed  that  perfor-
mance  status  and  stage  were  considered  independent
Table  2  Univariate  analysis  of  survival  time  by  categorical
variable.
Variable  Log-rank
test  value
Degrees  of
freedom
p
Sex  1.16  1  0.28
Age 0.29  1  0.86
Stage 5.39  1  0.02
Smoking  history  0.79  1  0.37
Performance  status  19.2  1  <0.001
Weight loss  0.1  1  0.90
Diabetes  mellitus  3.72  1  0.05
SUVmax,  median  0.18  1  0.66
Laboratory
parameters,  median
1
Albumin  2.45  1  0.11
LDH 1.05  1  0.30
Blood sugar  1.73  1  0.18
0,4
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0,0
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Figure  2  Survival  of  patients  according  to  stage.
rognostic  factors  for  survival  (p  <  0.001  and  p  =  0.002
espectively)  (Figs.  1 and  2).
iscussionCLC  is  very  sensitive  to  radiotherapy  and  chemotherapy
hile  it  is  associated  with  a  faster  tumor  doubling  time,
 high  growth  fraction  and  early  widespread  dissemination.
2A
a
s
o
t
ﬁ
A
w
Z
n
a
a
p
t
t
f
w
s
f
a
t
I
t
t
S
f
e
8
m
i
o
t
t
o
1
p
l
m
e
q
w
g
o
1
l
p
g
s
t
p
u
t
t
i
m
c
t
a
E
P
d
a
C
f
t
s
i
R
o
s
i
C
T
R
164  
s  a  result  of  this,  overall  survival  rates  for  these  patients
re  disappointingly  low.  Patients  eligible  for  chemotherapy
hould  be  selected  very  carefully.
There  are  a  number  of  studies  about  this  activity  as  shown
n  FDG  PET  in  relation  to  survival  in  SCLC14--17;  the  impor-
ance  of 18F-FDG-PET/CT  for  survival  in  patients  receiving
rst-line  EP  chemotherapy  is  still  subject  to  controversy.
lthough  Lee  et  al.15 showed  that  the  degree  of  SUVmax
as  strongly  associated  with  an  increase  in  overall  survival,
hu  et  al.14 and  Van  der  Leest  et  al.17 on  the  contrary  found
o  observable  prognostic  value  of  SUVmax.  In  our  multivari-
te  analysis,  we  found  that  SUVmax  value  was  not  a  factor
ssociated  with  survival.  The  inconsistency  of  results  may  be
artly  explained  by  blood  glucose  level  of  the  patient,  time
o  imaging,  the  biological  characteristics  of  tumor  cells  and
reatment  modality.
A  poor  PS  is  usually  accepted  as  a  negative  prognostic
actor  for  all  cancer  patients.18--20 The  importance  of  PS
as  also  conﬁrmed  in  advanced  SCLC  patients.15 Our  study
howed  that  poor  PS  is  an  associated  independent  risk
actor  for  survival.
The  median  survival  for  limited  disease  is  14--16  months
nd  only  8--11  months  for  extensive  disease  with  effective
reatment.  The  overall  5-year  survival  rate  is  under  10%.1,21
n  previous  studies,  many  authors14,15,17 have  shown  that
he  tumor  stage  at  initial  presentation  was  the  most  impor-
ant  prognostic  factor  for  survival  in  patients  with  SCLC.
imilarly,  stage  was  found  to  be  an  independent  prognostic
actor  of  survival  in  the  present  study.  In  our  study,  the
stimated  median  OS  for  LD  was  17.3  months  (95%  CI,
.9--25.7  months)  and  only  8.4  months  (95%  CI,  7.1--9.8
onths)  for  ED.
The  present  study  has  got  some  limitations.  Firstly,  it
s  based  on  retrospective  studies.  Secondly,  the  number
f  patients  was  small.  Thirdly,  we  did  not  evaluate  the
ype  of  DM,  duration  of  diabetes  and  the  types  of  diabetic
herapy  used.  Fourthly,  the  limit  described  of  150  mg/dl
f  patient  blood  glucose  level  may  lower  the  sensitivity  of
8F-FDG-PET/CT.  A  number  of  the  studies  have  shown  that
lasma  glucose  competes  with 18F-FDG  uptake  of  malignant
esions;  for  this  reason  it  is  claimed  that  hyperglycemia
ay  reduce  and  impair 18F-FDG  uptake  of  tumors.22--25 How-
ver,  Mirpour  et  al.26 and  Roy  et  al.27 showed  that  the
uality  of  PET/CT  images  is  sufﬁcient  to  provide  a  trust-
orthy  clinical  opinion,  even  in  those  patients  with  serum
lucose  level  above  180  mg/dL.  Accordingly,  the  Society
f  Nuclear  Medicine  guidelines  for  PET/CT  advocates  that
8F-FDG  should  not  be  administered  when  plasma  glucose
evel  is  over  150--200  mg/dL  (8.3--11.1  mmol/L).28 The  Euro-
ean  Association  of  Nuclear  Medicine  also  recommends  that
lycemia  should  ideally  not  exceed  130  mg/dL,  and  the  test
hould  be  rescheduled  if  the  serum  glucose  level  is  higher
han  200  mg/dL  (7.2  mmol/L).29 In  fact,  there  are  several
oints  of  controversy  outstanding.  The 18F-FDG  tumoural
ptake  process  in  hyperglycemia  is  not  yet  fully  understood.
In  conclusion,  performance  status  and  stage  were  iden-
iﬁed  as  important  prognostic  factors,  while  FDG  uptake  of
he  primary  lesions  was  not  associated  with  the  prognostic
mportance  for  survival  in  patients  with  SCLC.  These  ﬁndings
ay  also  facilitate  pretreatment  prediction  of  survival  and
an  be  used  for  selecting  patients  for  the  correct  choice  of 1A.  Inal  et  al.
reatment.  Therefore,  prospective  and  larger  clinical  trials
re  needed.
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